Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HPV vaccines.

Margaret Stanley1

  • 1Department of Pathology, Tennis Court Road, Cambridge CB2 1QP, UK. mas@mole.bio.cam.ac.uk

Best Practice & Research. Clinical Obstetrics & Gynaecology
|December 17, 2005
PubMed
Summary
This summary is machine-generated.

Human papillomavirus (HPV) virus-like particle vaccines show promise for preventing cervical cancer. Further research is needed on protection duration and developing new vaccines for broader application.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Knowledge and acceptability of male HPV vaccination among young people and community stakeholders in northwest Tanzania: social sciences in the Add-Vacc trial.

Vaccine·2025
Same author

Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trials.

The Lancet. Respiratory medicine·2025
Same author

Impact of human papillomavirus vaccines in the reduction of infection, precursor lesions, and cervical cancer: A systematic literature review.

Human vaccines & immunotherapeutics·2025
Same author

Evidence for an HPV one-dose schedule.

Vaccine·2024
Same author

Overview of CHIC symposia series: Summary of Africa and South Asia symposia.

Vaccine·2024
Same author

An update on one-dose HPV vaccine studies, immunobridging and humoral immune responses - A meeting report.

Preventive medicine reports·2023
Same journal

A risk-based classification of late-onset fetal growth disorders according to intrapartum fetal compromise.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

The Cardiac-Fetal-Placental Unit: links between umbilical venous flow and maternal hemodynamics in fetal growth restriction.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

Psychosocial interventions for women who are pregnant following a previous reproductive loss: A scoping review.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

Controversies in fetal therapy.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

Alloimmunisation in pregnancy: current management and future perspectives.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

Consensus in prenatal management of Hemolytic disease of the fetus and newborn.

Best practice & research. Clinical obstetrics & gynaecology·2026
See all related articles

Area of Science:

  • Virology
  • Vaccinology
  • Oncology

Background:

  • Human papillomavirus (HPV) infections are a leading cause of cervical carcinoma.
  • The development of HPV virus-like particle (VLP) vaccines, utilizing the major capsid protein L1, has revolutionized prevention strategies.
  • VLPs are immunogenic, safe, and effective in preventing persistent HPV infection and cervical intraepithelial neoplasia.

Purpose of the Study:

  • To evaluate the prospects of HPV VLP vaccines in preventing cervical cancer.
  • To identify limitations of current HPV vaccines, including duration of protection and type-specificity.
  • To explore potential improvements for second-generation vaccines and therapeutic approaches.

Main Methods:

  • Synthesis and in vitro self-assembly of HPV L1 protein to generate virus-like particles.

Related Experiment Videos

  • Analysis of immunogenicity and safety data from proof-of-principle efficacy trials.
  • Review of existing literature on HPV vaccine efficacy, duration, and antibody responses.

    • Main Results:

    • HPV VLPs have demonstrated strong potential for preventing cervical cancer.
    • Current vaccines induce type-specific antibody responses and require pre-exposure immunization.
    • The duration of protection offered by current HPV vaccines remains unknown.

    Conclusions:

    • HPV VLP vaccines represent a significant advancement in cervical cancer prevention.
    • Future vaccine development should focus on extending protection duration and broadening HPV type coverage.
    • Therapeutic vaccines show promise for low-grade disease, but high-grade disease requires further investigation.